MA37645A2 - Stabilized formulations containing anti-dll4 antibodies - Google Patents

Stabilized formulations containing anti-dll4 antibodies

Info

Publication number
MA37645A2
MA37645A2 MA37645A MA37645A MA37645A2 MA 37645 A2 MA37645 A2 MA 37645A2 MA 37645 A MA37645 A MA 37645A MA 37645 A MA37645 A MA 37645A MA 37645 A2 MA37645 A2 MA 37645A2
Authority
MA
Morocco
Prior art keywords
formulations containing
containing anti
dll4 antibodies
stabilized formulations
present
Prior art date
Application number
MA37645A
Other languages
Arabic (ar)
French (fr)
Other versions
MA37645A3 (en
MA37645B1 (en
Inventor
Scott Walsh
Daniel Dix
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37645(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA37645A2 publication Critical patent/MA37645A2/en
Publication of MA37645A3 publication Critical patent/MA37645A3/en
Publication of MA37645B1 publication Critical patent/MA37645B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبات صيدلانية تشتمل على جسم مضاد يرتبط بشكل خاص بمركب ترابطي شبيه بدلتنا 4d114 يمكن أن تشتمل الصيغ، بالإضافة إلى الجسم المضاد ل d114 على محلول منظم من الفوسفات ومذيب مشترك عضوي وسكاريد ثنائي وملح . وتبدي الصيغ الصيدلانية من الاختراع الحالي درجة عالية من الثبات الخاصة بالجسم المضاد بعد التخزين لعدة أشهر وبعد التعرض للحرارة والضغوط الفيزيائية الأخرىThe present invention relates to pharmaceutical compositions comprising an antibody specifically associated with a bind compound similar to our suit 4d114. The pharmaceutical formulas of the present invention demonstrate a high degree of stability of the antibody after storage for several months and after exposure to heat and other physical pressures

MA37645A 2012-05-31 2013-05-31 Stabilized formulations containing anti-dll4 antibodies MA37645B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31
PCT/US2013/043516 WO2013181486A1 (en) 2012-05-31 2013-05-31 Stabilized formulations containing anti-dll4 antibodies

Publications (3)

Publication Number Publication Date
MA37645A2 true MA37645A2 (en) 2016-08-31
MA37645A3 MA37645A3 (en) 2017-07-31
MA37645B1 MA37645B1 (en) 2018-10-31

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37645A MA37645B1 (en) 2012-05-31 2013-05-31 Stabilized formulations containing anti-dll4 antibodies

Country Status (30)

Country Link
US (1) US9675692B2 (en)
EP (1) EP2854849B1 (en)
JP (1) JP6144758B2 (en)
KR (1) KR20150033615A (en)
CN (1) CN104349791A (en)
AR (1) AR092325A1 (en)
AU (1) AU2013267301B2 (en)
BR (1) BR112014028997A2 (en)
CA (1) CA2872275C (en)
CL (1) CL2014003237A1 (en)
CO (1) CO7151478A2 (en)
DK (1) DK2854849T3 (en)
EA (1) EA029779B1 (en)
ES (1) ES2668900T3 (en)
HK (1) HK1207305A1 (en)
IL (1) IL235468A0 (en)
LT (1) LT2854849T (en)
MA (1) MA37645B1 (en)
MX (1) MX357146B (en)
NO (1) NO2887943T3 (en)
NZ (1) NZ702288A (en)
PH (1) PH12014502429A1 (en)
PL (1) PL2854849T3 (en)
PT (1) PT2854849T (en)
SG (1) SG11201407171XA (en)
SI (1) SI2854849T1 (en)
SM (1) SMT201800216T1 (en)
TW (1) TWI609696B (en)
UY (1) UY34842A (en)
WO (1) WO2013181486A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
LT3485903T (en) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/dll4 binding agents and uses thereof
ES2808153T3 (en) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Combination therapy for disease treatment
JP6781508B2 (en) * 2014-11-18 2020-11-04 塩野義製薬株式会社 Stabilized peptide composition
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US20210379186A1 (en) * 2018-04-16 2021-12-09 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
CN120241997A (en) 2019-02-18 2025-07-04 伊莱利利公司 Therapeutic antibody preparations
MX2022016218A (en) * 2020-07-08 2023-03-31 Regeneron Pharma Stabilized formulations containing anti-ctla-4 antibodies.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (en) 1986-10-15 1995-05-24 株式会社大協精工 Stacked syringe stopper
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (en) 1992-01-23 2000-10-23 株式会社大協精工 Modified polysiloxane composition and sanitary rubber product coated with the composition
ES2301158T3 (en) 1992-07-24 2008-06-16 Amgen Fremont Inc. XENOGENIC ANTIBODY PRODUCTION.
JP3172057B2 (en) 1995-04-05 2001-06-04 株式会社大協精工 Laminated rubber stopper
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
JP3512349B2 (en) 1999-01-29 2004-03-29 株式会社大協精工 Mold for columnar rubber element
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP5485489B2 (en) 2000-08-11 2014-05-07 中外製薬株式会社 Antibody-containing stabilized preparation
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (en) 2001-01-19 2002-07-30 Daikyo Seiko Ltd Laminated rubber stopper for pharmaceutical vials
MXPA04000747A (en) 2001-07-25 2004-07-08 Protein Desing Labs Inc Stable lyophilized pharmaceutical formulation of igg antibodies.
CN101721362B (en) 2002-02-14 2018-07-03 中外制药株式会社 Pharmaceutical solutions comprising antibody
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
MXPA05010555A (en) 2003-04-04 2006-03-09 Genentech Inc High concentration antibody and protein formulations.
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
ES2633574T3 (en) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations
BRPI0611901A2 (en) 2005-06-14 2012-08-28 Amgen, Inc composition, lyophilized kit and process for preparing a composition
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
CA2667466A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
RU2448979C2 (en) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Human antibodies to delta-like human ligand-4
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
HUE029661T2 (en) * 2009-10-16 2017-03-28 Oncomed Pharm Inc Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
EP2501408B1 (en) 2009-11-20 2020-05-27 Biocon Limited Formulations of antibody
KR101853278B1 (en) * 2010-03-02 2018-05-02 애브비 인코포레이티드 Therapeutic dll4 binding proteins
NZ609557A (en) * 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies

Also Published As

Publication number Publication date
SI2854849T1 (en) 2018-05-31
TW201400130A (en) 2014-01-01
CN104349791A (en) 2015-02-11
WO2013181486A1 (en) 2013-12-05
EP2854849A1 (en) 2015-04-08
EA201492186A1 (en) 2015-08-31
SMT201800216T1 (en) 2018-05-02
US9675692B2 (en) 2017-06-13
SG11201407171XA (en) 2014-11-27
PH12014502429B1 (en) 2015-01-12
PL2854849T3 (en) 2018-07-31
US20130323260A1 (en) 2013-12-05
KR20150033615A (en) 2015-04-01
BR112014028997A2 (en) 2017-07-25
NO2887943T3 (en) 2018-05-05
MA37645A3 (en) 2017-07-31
MA37645B1 (en) 2018-10-31
NZ702288A (en) 2016-12-23
DK2854849T3 (en) 2018-04-30
AU2013267301B2 (en) 2018-02-08
UY34842A (en) 2013-12-31
JP6144758B2 (en) 2017-06-07
CL2014003237A1 (en) 2015-07-10
CA2872275C (en) 2021-05-18
EA029779B1 (en) 2018-05-31
CA2872275A1 (en) 2013-12-05
PH12014502429A1 (en) 2015-01-12
MX357146B (en) 2018-06-28
JP2015520173A (en) 2015-07-16
AU2013267301A1 (en) 2014-12-18
HK1207305A1 (en) 2016-01-29
AR092325A1 (en) 2015-04-15
MX2014014363A (en) 2015-02-05
PT2854849T (en) 2018-05-09
LT2854849T (en) 2018-05-10
ES2668900T3 (en) 2018-05-23
CO7151478A2 (en) 2014-12-29
EP2854849B1 (en) 2018-02-28
TWI609696B (en) 2018-01-01
IL235468A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
MA37645A2 (en) Stabilized formulations containing anti-dll4 antibodies
JOP20180103A1 (en) Pharmaceutical composition
CY1121843T1 (en) MAGNESIUM ION STABILIZED RECEPTOR FORMULATIONS
EA201300200A1 (en) N - ((6-AMINOPIRIDIN-3-IL) METHYL) HETEROARILKARBOXAMIDES AS KALLYCREIN INHIBITORS IN PLASMA
EA201290183A1 (en) BENZODIAZEPINUM INHIBITOR BROMODOMENE
EA201791717A1 (en) STABLE WATER COMPOSITIONS ADALIMUMAB
EA201500926A1 (en) FUMARATES AS A DEVELOPMENT AND THEIR APPLICATION IN THE TREATMENT OF DIFFERENT DISEASES
BR112016008576A2 (en) STABLE AQUEOUS FORMULATIONS OF ANTIBODIES AND PHARMACEUTICAL UNIT DOSAGE FORM
EA201591003A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
EA201690247A1 (en) AMINOMETHYBYRIL DERIVATIVES-INHIBITORS OF COMPLEX D FACTOR AND USE
UA110612C2 (en) DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYRBORONIC ACID
BR112015000229A2 (en) stable aqueous formulations of etanercept
EA201300388A1 (en) COMPOUNDS OF SUBSTITUTED BENZAMIDE
UY32704A (en) COMPOUNDS OF 2,3-DIHIDRO-1H-INDENO
EA201400365A1 (en) NEW THYRODUCT LACTS AS HIGHLY ACTIVE HDAC INHIBITORS AND THEIR APPLICATION AS MEDICINES
EA201301061A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING INOSITIS
EA201491471A1 (en) COMPOSITION CONTAINING ANTIBODY AGAINST IL-17
EA201391555A1 (en) COMPOSITIONS OF SUSPENSION TYPE FOR LOCAL APPLICATION CONTAINING CYCLIC DEPSYPETPID
EA201501163A1 (en) CXCR7 RECEPTOR MODULATORS
EA201400444A1 (en) DERIVATIVES 2-OXOPYPERIDINYL
UA110822C2 (en) Piperidine monocarboxylic acid as agonists s1p1-receptor
ECSP13012481A (en) ANTI-VEGFR-3 ANTIBODY COMPOSITIONS
EA201171414A1 (en) IAP FAMILY INHIBITORS
UA103290C2 (en) Pharmaceutical composition of ibuprofen for injection
EA201492280A1 (en) STABLE PEXIGANANE COMPOSITION